Rani Therapeutics (RANI) CTO discloses initial stock, RSU and option holdings

Rhea-AI Filing Summary

Rani Therapeutics Holdings, Inc. executive Alireza Javadi, Chief Technical Officer, reported his initial ownership of company securities. He directly holds 10,075 shares of Class A common stock, including 4,297 restricted stock units that vest in equal monthly installments from June 27, 2023 through March 27, 2027, subject to continued service.

He also holds several stock option awards over Class A common stock with exercise prices ranging from $0.6168 to $13.2100 per share and expirations between 2032 and 2035. One option grant is fully vested, while others vest monthly or in 25% annual installments over four-year periods beginning on December 27, 2023, March 21, 2024, and May 23, 2025, all contingent on his continued service.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Javadi Alireza

(Last) (First) (Middle)

C/O RANI THERAPEUTICS HOLDINGS, INC.

2051 RINGWOOD AVENUE

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
Rani Therapeutics Holdings, Inc. [ RANI ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Class A Common Stock	10,075(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	03/21/2032	Class A Common Stock	9,166	$13.21	D
Stock Option (Right to Buy)	(2)	03/26/2033	Class A Common Stock	3,416	$5.44	D
Stock Option (Right to Buy)	(2)	12/14/2033	Class A Common Stock	10,834	$2.84	D
Stock Option (Right to Buy)	(3)	12/14/2033	Class A Common Stock	17,084	$2.84	D
Stock Option (Right to Buy)	(4)	03/20/2034	Class A Common Stock	40,750	$3.6	D
Stock Option (Right to Buy)	(5)	05/22/2035	Class A Common Stock	159,000	$0.6168	D

Explanation of Responses:

1. Includes 4,297 shares of restricted stock units (RSUs) subject to vesting in equal monthly installments beginning June 27, 2023 through March 27, 2027 and Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

2. The shares subject to the option are fully vested.

3. The shares subject to this option vest 1/48th monthly over a four-year period beginning on December 27, 2023, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) with the Company through each vesting date.

4. The shares subject to this option vest 25% each year over a four-year period beginning on March 21, 2024, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) with the Company through each vesting date.

5. The shares subject to this option vest 25% each year over a four-year period beginning on May 23, 2025, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) with the Company through each vesting date.

	/s/ Svai Sanford, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does Rani Therapeutics (RANI) CTO Alireza Javadi report in this Form 3?

The Form 3 shows CTO Alireza Javadi’s initial ownership in Rani Therapeutics, including 10,075 Class A common shares and multiple stock option awards. It establishes his baseline equity position as an officer, combining direct stock, RSUs, and unexercised options with long-dated expirations.

How many Rani Therapeutics (RANI) common shares does the CTO directly hold?

Alireza Javadi directly holds 10,075 shares of Rani Therapeutics Class A common stock. This total includes 4,297 restricted stock units that vest monthly through March 27, 2027, subject to his continued service under the company’s 2021 Equity Incentive Plan.

What restricted stock units (RSUs) are disclosed for Rani Therapeutics (RANI) CTO?

The filing discloses 4,297 RSUs for the CTO, each representing one share of common stock. These RSUs vest in equal monthly installments from June 27, 2023 through March 27, 2027, conditioned on his continued service with Rani Therapeutics at each vesting date.

What stock option holdings does the Rani Therapeutics (RANI) CTO report?

The CTO reports several stock options to buy Class A common stock with exercise prices between $0.6168 and $13.2100 per share and expirations from 2032 to 2035. One grant is fully vested, while others vest monthly or annually over four-year schedules.

How do the CTO’s option vesting schedules work at Rani Therapeutics (RANI)?

Certain options vest 1/48th monthly over four years starting December 27, 2023. Others vest 25% each year over four-year periods beginning March 21, 2024 and May 23, 2025, all subject to Alireza Javadi maintaining continuous service with the company.

Does this Rani Therapeutics (RANI) Form 3 show any insider share purchases or sales?

The Form 3 functions as an initial ownership report and does not show explicit open-market purchases or sales. It lists the CTO’s existing common stock, RSU awards, and unexercised stock options as of the reporting date, rather than new trading activity.